| Similar Articles |
|---|
 |
The Motley Fool
September 4, 2009
Brian Orelli |
Takeover Likely? Management Says No! A hostile bid that management didn't want. Biogen Idec announced today that it's willing to buy Facet Biotech for $14.50 per share.   |
The Motley Fool
March 10, 2010
Brian Orelli |
You Paid How Much for That? Abbott steps up where Biogen Idec wouldn't. |
The Motley Fool
December 16, 2009
Brian Orelli |
No Holiday Goodwill Twixt Biogen and Facet Biogen and Facet are still at it, as their nasty takeover fight continues. |
The Motley Fool
May 2, 2007
Brian Lawler |
Biogen's Measured Growth The biopharmaceutical reports first-quarter financial results. Investors, take note. |
The Motley Fool
December 13, 2007
Brian Lawler |
Biogen Can't Find a Buyer After formally putting itself up for sale two months ago, Biogen Idec announces that it can't find any takers. |
The Motley Fool
October 16, 2007
Brian Lawler |
Questions Surround a Biogen Deal Rumors swirl around Biogen after it publicly announces that it's for sale. Investors, take note. |
The Motley Fool
April 21, 2011
Brian Orelli |
Tysabri Means Everything to Biogen and Elan ... for Now It's rare to find a drug that affects two companies as much as Tysabri does Biogen Idec and Elan. |
The Motley Fool
August 7, 2009
Brian Orelli |
A Billion-Dollar Lovers' Quarrel It looks like the triangle between partners Elan and Biogen Idec and third-wheel Johnson & Johnson over the multiple sclerosis drug Tysabri is going to get settled in court. |
The Motley Fool
July 26, 2006
Brian Lawler |
Biogen Slows Down Several potential growth drivers should help the biopharma. Ever since the merger with Idec, the company has been fairly well run (absent the Tysabri delays). Investors, take note. |
The Motley Fool
June 8, 2010
Ryan McBride |
Biogen's CEO Retires, COO to Follow A replacement won't be announced for a few weeks. |
The Motley Fool
November 8, 2007
Brian Lawler |
Let the Biogen Bidding Begin Speculation of bidding by big-pharma companies for Biogen IDEC cause the shares to rise. Investors, take note. |
The Motley Fool
February 7, 2008
Brian Lawler |
Biogen Rests Rumors The pharmaceutical announces its year-end financial results, and squashes rumors that it is considering a major acquisition. |
The Motley Fool
October 15, 2007
Brian Lawler |
PDL BioPharma's Best Hope The data on daclizumab for multiple sclerosis is encouraging. Investors, take note. |
The Motley Fool
September 15, 2009
Brian Orelli |
What's $115 Million Between Friends? Elan has to fix the mess it had gotten itself into with its multiple sclerosis drug Tysabri. |
The Motley Fool
June 11, 2008
Brian Lawler |
He Said, Biogen Said Pharmaceutical Biogen Idec's battle with Carl Icahn is coming to a head. |
The Motley Fool
February 8, 2005
Charly Travers |
Good Prognosis for Biogen IDEC Blockbuster products help the biotech firm continue its stellar performance. |
The Motley Fool
March 16, 2007
Brian Lawler |
PDL's Friend Comes Through PDL and partner Biogen advance one of their lead drug candidates. Investors, take note. |
The Motley Fool
October 31, 2011
Brian Orelli |
When You've Got It, You've Got It Biogen keeps its good-news streak going. |
The Motley Fool
August 19, 2010
Brian Orelli |
High Risk, High Reward. At Least It Was Cheap! Biogen licenses a drug to treat ALS. |
The Motley Fool
April 12, 2011
Brian Orelli |
How Significant Is 'Statistically Significant' for Biogen? Biogen could have a third multiple sclerosis blockbuster on its hands. |
The Motley Fool
April 25, 2008
Brian Lawler |
Biogen's Big Step Forward Pharmaceutical company Biogen IDEC boasts better results and a rosier outlook. |
The Motley Fool
January 5, 2010
Brian Orelli |
Biogen Idec's CEO Calls It Quits And the market seems to be saying to him don't let the door hit you on the way out. |
The Motley Fool
July 23, 2008
Brian Lawler |
No Picking at Biogen At a time in which all of its top drugs experienced at least double-digit percentage sales growth, there aren't many issues to poke at with Biogen Idec's just-released second-quarter financial results. |
The Motley Fool
September 4, 2009
Brian Orelli |
The Billion-Dollar Lovers' Quarrel Continues Elan had better bring candy and flowers to patch this up. |
The Motley Fool
March 8, 2005
Charly Travers |
After the Crash, Is Biogen IDEC a Buy? Biogen stock plunge may be an overreaction to pulling multiple sclerosis drug Tysabri off the market. |
The Motley Fool
May 26, 2004
Charly Travers |
Elan and Biogen File for Approval There's a new multiple sclerosis drug on the horizon. |
The Motley Fool
July 24, 2007
Brian Lawler |
Biogen's Steady Growth Biogen reports another good quarter of growth, both top- and bottom-line. |
The Motley Fool
May 18, 2010
Brian Orelli |
What Astellas' Purchase of OSI Means for Biotech Investors Stop buying for the potential takeout. |
The Motley Fool
April 22, 2011
MedCity News |
Biogen Idec's MS Drug Appears to Have an Edge Trial results give the company an advantage in oral MS treatments. |
The Motley Fool
May 29, 2008
Brian Lawler |
Icahn Girds for Biogen Battle The activist investor officially launches his bid to usurp Biogen's board of directors. |
The Motley Fool
February 10, 2010
Brian Orelli |
Icahn's Smiling -- Should We Be? Biogen Idec's fourth quarter results must have made Carl Icahn smile. But the guidance for next year gives pause. |
The Motley Fool
August 3, 2005
Charly Travers |
Biotech's Big Deal The market is pleased with the partnership between Protein Design Labs and Biogen IDEC. |
The Motley Fool
January 21, 2011
Brian Orelli |
Trouble in Tysabri Land? Patient additions for a drug from Biogen Idec and Elan are slowing down. |
The Motley Fool
January 29, 2008
Brian Lawler |
Icahn Tries to Board USS Biogen Carl Icahn and the funds that he runs announce that they will try to get elected to three seats on the board of directors at Biogen Idec. |
The Motley Fool
July 21, 2010
Brian Orelli |
Biogen Looks Good Now, but What About Tomorrow? Biogen Idec saw revenue increase 11% and adjusted earnings per share jump almost 75%, which is all well and good, but the longer-term prospects for the company aren't nearly as impressive. |
The Motley Fool
June 30, 2010
Ryan McBride |
Reports: Biogen Picks Exelixis Chief George Scangos as New CEO George Scangos, a microbiologist by training, has been CEO of the South San Francisco-based cancer drug developer Exelixis since 1996, and takes over at Biogen immediately. |
The Motley Fool
April 17, 2009
Brian Orelli |
When Revenue Trumps Earnings Biogen grows earnings, but what does that say about the future? |
The Motley Fool
May 26, 2009
Brian Orelli |
Buy Now! It Might Get Bought! Clinical trial results and FDA approvals ultimately drive any increase in drugmakers' value. That's what pharmaceutical investors should focus on. The potential for an acquisition should be nothing more than icing on the cake. |
The Motley Fool
October 24, 2007
Brian Lawler |
Biogen's Brisk Business Following a rumor-filled and busy couple of weeks, Biogen releases its third-quarter financial results. |
The Motley Fool
September 14, 2009
Brian Orelli |
The Clock Is Ticking for Elan Elan is getting closer to the Sept. 26 deadline to fix its contract with Johnson & Johnson. If it doesn't, Biogen Idec has the right to take full control of Elan's and Biogen's multiple-sclerosis drug, Tysabri. |
Chemistry World
February 8, 2013
Andrew Turley |
Biogen buys Tysabri from Elan for $3.25bn US biotech Biogen Idec is to pay $3.25 billion to Irish drugmaker Elan for full rights to Tysabri (natalizumab) injections for the treatment of multiple sclerosis. |
The Motley Fool
August 10, 2010
Brian Orelli |
Elan's Alternative to Strategic Alternatives Sometimes doing nothing is the best option. |
The Motley Fool
November 1, 2006
Brian Lawler |
Biogen Idec's Booming Results Even with guidance for 2006 non-GAAP earnings per share raised to more than $2.20, Biogen shares are trading at a reasonable 24 times earnings, considering the level of scale and sales growth it has exhibited this year. |
The Motley Fool
April 29, 2011
Brian Orelli |
Oral Multiple Sclerosis Drugs Heat Up Watch out Novartis and Gilenya. |
The Motley Fool
May 31, 2007
Tim Beyers |
Biogen's $3 Billion Bet There are times when a buyback is not only appropriate, but also smart. This is one of those times for Biogen Idec. It's a chance for management to deliver huge returns to long-suffering shareholders. |
The Motley Fool
February 6, 2009
Brian Orelli |
Icahn vs. Biogen: Round 2 On the heels of an announcement that he'll try to get seats on Amylin Pharmaceuticals' board, Icahn is also angling for seats on Biogen Idec's board. |
The Motley Fool
October 28, 2011
Brian Orelli |
Focus on Profits, Biotech Investors Elan is in the black and looking as healthy as ever. |
The Motley Fool
January 9, 2008
Brian Lawler |
Checking In on Biogen Biogen Idec presents at the JPMorgan Healthcare Conference, reiterating its long-term guidance of 15% compound annual sales growth and 20% average non-GAAP earnings-per-share growth from 2007 through 2010. |
The Motley Fool
April 22, 2010
Brian Orelli |
Abbott's Stuck in a Double-Digit Rut The company keeps cranking out solid earnings, but investors don't seem to care. |
The Motley Fool
December 19, 2011
Brian Orelli |
Elan Turns It Around in 2011 Let's hope next year is as productive. |
